PDF Cover

SMA Newborn Screening Market

The market for SMA Newborn Screening was estimated at $483 million in 2024; it is anticipated to increase to $823 million by 2030, with projections indicating growth to around $1.28 billion by 2035.

Report ID:DS1801354
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
SMA Newborn Screening
Share
Report Summary
Market Data
Methodology
Table of Contents

Global SMA Newborn Screening Market Outlook

Revenue, 2024

$483M

Forecast, 2034

$1.17B

CAGR, 2025 - 2034

9.3%

The SMA Newborn Screening industry revenue is expected to be around $527.5 million in 2025 and expected to showcase growth with 9.3% CAGR between 2025 and 2034. Building on this growth trajectory, SMA newborn screening is gaining strong clinical and public health importance as healthcare systems increasingly prioritize early detection of rare genetic disorders. Rising awareness among pediatric specialists and parents, combined with expanding government-led screening programs, is significantly improving early diagnosis rates. Advances in molecular diagnostic technologies, including PCR-based and next-generation sequencing methods, are enhancing screening accuracy and turnaround time. Additionally, increasing healthcare expenditure and supportive reimbursement frameworks in developed economies are further strengthening adoption. The growing emphasis on preventive healthcare and early intervention strategies is making SMA screening an essential component of neonatal care pathways across hospitals and diagnostic laboratories, ensuring better patient outcomes and reduced long-term treatment burdens.

SMA newborn screening refers to diagnostic testing performed shortly after birth to detect spinal muscular atrophy, a severe genetic neuromuscular disorder caused by SMN1 gene mutations. It primarily utilizes dried blood spot samples and advanced molecular assays to identify affected newborns before symptom onset. Key features include high sensitivity, early detection capability, and integration into national newborn screening panels in several countries. Major applications include hospital-based neonatal screening programs, public health initiatives, and genetic counseling services. Recent trends driving demand include the expansion of mandatory newborn screening policies, increasing availability of gene-targeted therapies, and rising collaboration between diagnostic companies and healthcare institutions. The shift toward precision medicine and early therapeutic intervention is further strengthening the role of SMA screening in modern neonatal healthcare systems globally.

SMA Newborn Screening market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
SMA Newborn Screening Market Outlook

Market Key Insights

  • The Sma Newborn Screening market is projected to grow from $482.6 million in 2024 to $1.17 billion in 2034. This represents a CAGR of 9.3%, reflecting rising demand across Early Detection of Spinal Muscular Atrophy, Carrier Testing, and Prenatal Diagnosis.

  • PerkinElmer Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Sma Newborn Screening market and are expected to observe the growth CAGR of 6.8% to 9.8% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.9% to 11.6%.

  • Transition like Transition from selective genetic testing to universal newborn screening programs is expected to add $82 million to the Sma Newborn Screening market growth by 2030.

  • The Sma Newborn Screening market is set to add $692 million between 2024 and 2034, with manufacturer targeting Diagnostic Laboratories & Public Health Laboratories Application projected to gain a larger market share.

  • With

    rising newborn genetic screening programs and expanding early diagnostic healthcare initiatives, and

    Advancements in molecular diagnostics and increasing adoption of gene targeted therapies globally, Sma Newborn Screening market to expand 143% between 2024 and 2034.

sma newborn screening market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
SMA Newborn Screening - Country Share Analysis

Opportunities in the SMA Newborn Screening

Developed regions such as the United States and Western Europe are also increasingly integrating SMA newborn screening with access to gene-targeted therapies, creating a strong value-driven ecosystem. Early detection programs are being closely linked with immediate therapeutic intervention pathways, significantly improving clinical outcomes. This integration encourages hospitals and state health systems to expand screening coverage. Next-generation sequencing and high-throughput molecular diagnostics are being adopted to enhance accuracy and reduce turnaround times. Strategic collaborations between pharmaceutical companies and diagnostic providers are further strengthening this ecosystem, making SMA screening a critical entry point for precision medicine-based neonatal care pathways in advanced healthcare systems.

Growth Opportunities in North America and Europe

North America represents the most advanced and structured market for SMA newborn screening, driven by strong public health mandates, widespread adoption of expanded newborn screening panels, and high awareness of genetic disorders. The United States leads the region, with SMA included in Recommended Uniform Screening Panel programs across many states, supporting early diagnosis and rapid treatment initiation. Key opportunities lie in integrating newborn screening with gene therapy pathways and expanding coverage in underserved rural populations. Competition is intense, with leading diagnostic and life science companies collaborating with hospitals, state health departments, and research institutions to strengthen screening infrastructure. Strong reimbursement frameworks, advanced laboratory networks, and rapid adoption of precision medicine further reinforce market growth, making North America a mature yet innovation-driven region with sustained demand for SMA genetic screening solutions.
Europe is experiencing steady expansion in SMA newborn screening, supported by increasing government-led initiatives and harmonized public health policies across several countries. Nations such as Germany, Italy, and parts of Scandinavia are actively integrating SMA into national newborn screening programs, improving early detection rates. Key opportunities include broader inclusion in universal screening frameworks and expansion of cross-border genetic testing collaborations. Competition is growing among regional diagnostic laboratories and global life science companies offering high-throughput molecular testing solutions. Drivers include strong healthcare infrastructure, rising awareness of rare diseases, and growing emphasis on preventive pediatric care. However, adoption varies across countries due to differing reimbursement systems and policy readiness, creating a mixed but steadily expanding market landscape for SMA screening services.

Market Dynamics and Supply Chain

01

Driver: Rising newborn genetic screening programs and expanding early diagnostic healthcare initiatives

The SMA newborn screening market is also strongly driven by the expansion of national newborn genetic screening programs alongside increasing emphasis on early diagnostic healthcare initiatives. Many countries are also integrating SMA testing into mandatory or recommended newborn screening panels, significantly improving early detection rates. This trend is also supported by public health policies focused on reducing infant mortality and long-term disability burdens. At the same time, hospitals and diagnostic laboratories are also adopting advanced molecular testing platforms, including PCR and next-generation sequencing, to enhance screening accuracy and turnaround time. These combined factors are also increasing testing volumes and standardizing SMA screening as part of routine neonatal care. Additionally, growing awareness among pediatricians and parents regarding early intervention benefits is also further accelerating adoption across both developed and emerging healthcare systems.
A major driver of the SMA newborn screening market is also the rapid advancement in molecular diagnostic technologies combined with the increasing availability of gene-targeted therapies. Innovations such as highly sensitive PCR-based assays and next-generation sequencing have also significantly improved the reliability and speed of SMA detection in newborns. These advancements enable earlier diagnosis, which is also critical for initiating life-changing treatments. At the same time, the approval and wider adoption of gene therapies and disease-modifying treatments are also increasing the clinical value of early screening. Healthcare providers are also more motivated to implement screening programs as early detection directly improves treatment outcomes. This synergy between diagnostics and therapeutics is also strengthening demand for SMA screening across hospitals, diagnostic centers, and public health systems worldwide.
02

Restraint: High implementation costs and limited infrastructure in low-resource regions

A major restraint for SMA newborn screening is the high cost and infrastructure required to implement and sustain these programs, particularly in low- and middle-income countries. Advanced molecular screening technologies and trained personnel are expensive, and many healthcare systems lack the laboratory facilities or funding to support widespread testing. This limits market expansion and creates uneven screening coverage across regions, reducing overall demand and revenue potential. For example, countries with constrained healthcare budgets may prioritize other public health needs over genetic screening programs, slowing adoption and reinforcing disparities in early SMA diagnosis.
03

Opportunity: Expansion of national newborn screening programs across emerging economies and Increasing demand for expanded carrier screening and reproductive genetic counseling services

Emerging economies such as India, Brazil, and parts of Southeast Asia present a significant opportunity for SMA newborn screening due to expanding national healthcare infrastructure and rising focus on preventive pediatrics. Governments are gradually integrating genetic disorders into routine newborn screening panels, creating large untapped patient pools. Public-private partnerships with diagnostic companies are accelerating pilot programs and pilot-to-national scale transitions. Cost-effective PCR-based testing platforms are gaining traction in these regions due to affordability and scalability. As awareness of rare genetic diseases improves among healthcare professionals, adoption of SMA screening in public hospitals and maternity centers is expected to rise substantially, driving long-term market penetration.
There is growing demand for SMA-related carrier screening and reproductive genetic counseling among prospective parents, particularly in urban populations with higher genetic awareness. This opportunity is expanding across private diagnostic laboratories, fertility clinics, and prenatal care centers. Multi-disease carrier screening panels that include SMA are becoming increasingly popular due to their cost efficiency and comprehensive risk assessment capabilities. Healthcare providers are leveraging digital health platforms and tele-genetics services to improve accessibility and patient engagement. As awareness of hereditary disease prevention increases, carrier screening is expected to become a key growth segment, complementing newborn screening and expanding the overall SMA diagnostic ecosystem.
04

Challenge: Inconsistent policy mandates and variable government support affecting adoption rates

Another key challenge is the lack of uniform government mandates and variable policy support for SMA newborn screening worldwide. While some countries have integrated SMA into national newborn screening panels, others lag due to differing healthcare priorities, regulatory hurdles, or slow legislative action. This inconsistency impacts demand behavior, as providers may hesitate to invest in screening capabilities without clear public health directives or reimbursement frameworks. The resulting fragmented market dynamics reduce competitive pressure and delay broader implementation, limiting overall market momentum and long-term growth opportunities.

Supply Chain Landscape

1

Raw Material Suppliers

Thermo Fisher ScientificRoche Diagnostics
2

Test Developers

PerkinElmerIllumina
3

Distribution & Logistics

FedExUPS
4

End Users

HospitalsDiagnostic Laboratories
SMA Newborn Screening - Supply Chain

Use Cases of SMA Newborn Screening in Early Detection of Spinal Muscular Atrophy & Prenatal Diagnosis

Early Detection of Spinal Muscular Atrophy : Early detection of spinal muscular atrophy is the primary application of SMA newborn screening and is most commonly performed using dried blood spot samples collected shortly after birth. Molecular diagnostic techniques such as PCR-based assays and multiplex ligation-dependent probe amplification are widely used to identify SMN1 gene deletions responsible for the disease. This application is critical in neonatal screening programs across hospitals and public health systems. Its key advantage lies in enabling diagnosis before symptom onset, allowing timely initiation of gene therapy or disease-modifying treatments. Early detection significantly improves survival rates and motor function outcomes, making it a cornerstone of modern preventive pediatric healthcare and national newborn screening initiatives.
Carrier Testing : Carrier testing for SMA is widely used in reproductive-age adults and prospective parents to identify individuals who carry one defective SMN1 gene copy. This application primarily relies on blood or saliva-based molecular genetic tests conducted in diagnostic laboratories and genetic counseling centers. It is especially important in preconception and family planning settings, where early identification of carrier status helps assess reproductive risk. The key advantage of carrier testing is its ability to support informed decision-making and reduce the likelihood of affected births through genetic counseling. Increasing awareness and accessibility of genetic screening services are driving its adoption in both developed and emerging healthcare systems.
Prenatal Diagnosis : Prenatal diagnosis of SMA is performed during pregnancy to detect genetic abnormalities in the fetus using procedures such as chorionic villus sampling or amniocentesis combined with molecular genetic testing. This application is typically offered in specialized maternal-fetal medicine units and high-risk obstetric care centers. It is particularly recommended for couples identified as carriers or those with a family history of SMA. The main advantage of prenatal diagnosis is early and accurate determination of fetal risk, enabling informed reproductive choices and early medical planning. Rising adoption of non-invasive prenatal testing technologies and expanding genetic counseling services are further enhancing its clinical importance globally.

Impact of Industry Transitions on the SMA Newborn Screening Market

As a core segment of the Medical Device industry, the SMA Newborn Screening market develops in line with broader industry shifts. Over recent years, transitions such as Transition from selective genetic testing to universal newborn screening programs and Transition toward integrated screening and early therapeutic intervention ecosystems have redefined priorities across the Medical Device sector, influencing how the SMA Newborn Screening market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from selective genetic testing to universal newborn screening programs

The SMA newborn screening industry is shifting from selective, risk-based genetic testing toward universal newborn screening integration in national healthcare systems. This transition is driven by increasing recognition of the importance of early detection before symptom onset. Many countries are expanding screening panels to include SMA as a standard test in newborn programs. For example, public health systems in the United States and parts of Europe have incorporated SMA screening into routine neonatal care, improving early diagnosis rates. This shift is significantly impacting diagnostic laboratories and hospital workflows by increasing testing volumes and standardizing genetic screening as a core component of preventive pediatric healthcare.
02

Transition toward integrated screening and early therapeutic intervention ecosystems

Another major transition is the movement from isolated diagnostic testing to integrated screening and treatment ecosystems. SMA newborn screening is increasingly linked directly with access to gene-targeted therapies and disease-modifying treatments. This ensures immediate clinical action after diagnosis, improving patient outcomes. For instance, healthcare networks are collaborating with pharmaceutical companies to streamline referral pathways from screening to treatment initiation. This transition is reshaping the pharmaceutical, diagnostics, and hospital sectors by creating coordinated care models. It is also increasing the strategic value of screening programs, as early detection is now closely tied to therapy eligibility and long-term healthcare cost reduction.